Other Articles |


Am J Dis Child. 1950;79(5):785-790. doi:10.1001/archpedi.1950.04040010802001.
Text Size: A A A
Published online

G A N T R I S I N,® 3,4-dimethyl-5-sulfanilamido-isoxazole, formerly known as NU-445, is a new sulfonamide which has as its advantages a high degree of solubility and low toxicity. Because of its solubility, there is no crystallization in the urine except with doses that are much higher than would be used therapeutically.

Bryer and his associates1 reported that the acute toxicity of gantrisin® is low in white mice. They found the drug comparable to sulfadiazine in its ability to protect mice against beta hemolytic streptococcus and pneumococcus infections. It is not as effective as sulfadiazine in experimental infections in mice produced by Klebsiella pneumoniae. Neither compound was protective against experimental infection produced by Hemophilus influenzae, type B. Sarnoff2 reported neither crystalluria nor signs of renal irritation in 36 patients treated with gantrisin.® He observed that the amount of the drug entering into the spinal fluid of


Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview





Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.